Cardiovascular Imaging Technologies   Report issue

For profit Phase 2 Phase 4
Founded: Kansas City MO United States (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2008
NCT00808314
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Timothy M. Bateman | Timothy M. Bateman, MD

Active Ingredients

Drugs in Phase 4 Trials (4)

dipyridamole (persantine) (1 trial)

iobenguane (123i) (1 trial)

regadenoson (lexiscan) (3 trials)

rubidium chloride rb-82 (1 trial)

Drugs in Phase 2 Trials (1)

99mtc ecdg (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 2)

Myocardial Ischemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5